These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21575258)

  • 21. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.
    Sakamoto H; Friel AM; Wood AW; Guo L; Ilic A; Seiden MV; Chung DC; Lynch MP; Serikawa T; Munro E; Oliva E; Orsulic S; Kirley SD; Foster R; Zukerberg LR; Rueda BR
    Cancer Biol Ther; 2008 Feb; 7(2):180-88. PubMed ID: 18059193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
    Pils D; Horak P; Vanhara P; Anees M; Petz M; Alfanz A; Gugerell A; Wittinger M; Gleiss A; Auner V; Tong D; Zeillinger R; Braicu EI; Sehouli J; Krainer M
    Cancer; 2013 Mar; 119(5):946-54. PubMed ID: 23096450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
    Buchholtz ML; Brüning A; Mylonas I; Jückstock J
    Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
    Yang H; Das P; Yu Y; Mao W; Wang Y; Baggerly K; Wang Y; Marquez RT; Bedi A; Liu J; Fishman D; Lu Z; Bast RC
    Oncotarget; 2016 Jan; 7(3):3018-32. PubMed ID: 26689988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
    Pavese JM; Ogden IM; Voll EA; Huang X; Xu L; Jovanovic B; Bergan RC
    PLoS One; 2014; 9(7):e102289. PubMed ID: 25019290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
    Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
    Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
    Qian B; Katsaros D; Lu L; Canuto EM; Benedetto C; Beeghly-Fadiel A; Yu H
    Oncol Rep; 2011 Jan; 25(1):203-13. PubMed ID: 21109978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
    Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
    BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
    Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
    Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation rate of MAP2K4/MKK4 in breast carcinoma.
    Su GH; Song JJ; Repasky EA; Schutte M; Kern SE
    Hum Mutat; 2002 Jan; 19(1):81. PubMed ID: 11754110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-κB signaling pathway.
    Wang S; Kang W; Go MY; Tong JH; Li L; Zhang N; Tao Q; Li X; To KF; Sung JJ; Yu J
    Mol Med; 2012 Dec; 18(1):1402-11. PubMed ID: 23073659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
    Ma L; Guo Q; Ma Y; Liu FR; Shen XY
    Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.